2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
3
Conditions
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
1265
Specimen Handling
926
Magnetic Resonance Spectroscopy
830
Carboplatin
823
Cyclophosphamide
800
Cisplatin
723
Nivolumab
669
Paclitaxel
627
Radiotherapy
611
Gemcitabine
573
Biopsy
557
Bevacizumab
478
Dexamethasone
438
fludarabine
407
Docetaxel
380
venetoclax
368
Oxaliplatin
364
Capecitabine
358
Fluorouracil
355
atezolizumab
350
durvalumab
332
Rituximab
330
Drug Therapy
326
Doxorubicin
316
Radiosurgery
315
Standard of Care
309
Blood Specimen Collection
308
Pemetrexed
305
Ipilimumab
299
Radiation
286
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
mitazalimab
×
1 year
×
Clear all
NCT07199764
2026-03-06
IGNITE
University of Pennsylvania
Phase 2
Recruiting
100 enrolled
NCT07437287
2026-02-27
CROCOBIL
UNICANCER
Phase 2/3
Not yet recruiting
160 enrolled
NCT04888312
2025-10-08
OPTIMIZE-1
Alligator Bioscience AB
Phase 1/2
Active not recruiting
94 enrolled